CLAIMS

1. A fusion polypeptide comprising two fibronectin type III tenth (^{10}Fn3) domains,

wherein the first ^{10}Fn3 domain comprises AB, BC, CD, DE, EF, and FG loops, wherein the CD loop comprises an amino acid sequence according to the formula G-X_1-X_2-V-X_3-X_4-X_5-S-X_6-X_7-G-X_8-X_9-Y-X_{10}-X_{11}-X_{12}-E, wherein,

(a) X_1 is selected from the group consisting of R or W;

(b) X_2 is selected from the group consisting of H, E, D, Y, or Q;

(c) X_3 is selected from the group consisting of Q or H;

(d) X_4 is selected from the group consisting of I, K, M, Q, L, or V;

(e) X_5 is selected from the group consisting of Y, F, or N;

(f) X_6 is selected from the group consisting of D, V, or E;

(g) X_7 is selected from the group consisting of L, W, or F;

(h) X_8 is selected from the group consisting of P or T;

(i) X_9 is selected from the group consisting of L or M;

(j) X_{10} is selected from the group consisting of I or V;

(k) X_{11} is selected from the group consisting of Y or F; and

(l) X_{12} is selected from the group consisting of T, S, Q, N, or A, and

wherein the polypeptide binds to human serum albumin with a K_D of less than 500 nM, and wherein the ^{10}Fn3 domain further binds to one or more of rhesus serum albumin, cynomolgus serum albumin, mouse serum albumin, and rat serum albumin with a K_D of less than 500 nM; and

wherein the second ^{10}Fn3 domain binds to Proprotein Convertase Subtilisin Kexin type 9 (PCSK9).

2. The fusion polypeptide of claim 1, wherein the CD loop of the first ^{10}Fn3 domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 101-125.

3. The fusion polypeptide of claim 1, wherein the first ^{10}Fn3 domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 23-100, 184-209 and 235-260.

4. The fusion polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 167-169, and 261.

5. A composition comprising a fusion polypeptide of any one of claims 1 to 4 and a carrier.

6. An isolated nucleic acid molecule encoding the fusion polypeptide of any one of claims 1 to 4.

7. The isolated nucleic acid molecule of claim 6, wherein the nucleic acid molecule comprises a sequence selected from the group consisting of SEQ ID NOs: 126-151 and 172.

8. An expression vector comprising a nucleotide sequence encoding the fusion polypeptide of any one of claims 1 to 4.

9. A cell comprising a nucleic acid molecule of claim 6 or 7 or the expression vector of claim 8.

10. A method of producing the fusion polypeptides of any one of claims 1 to 4 comprising culturing the cell of claim 9 under conditions suitable for expressing the polypeptide, and purifying the polypeptide.

11. Use of the fusion polypeptide of any one of claims 1 to 4 or the composition of claim 5 in the manufacture of a medicament for the treatment of atherosclerosis in a subject in need thereof.

12. Use of the fusion polypeptide of any one of claims 1 to 4 or the composition of claim 5 i the manufacture of a medicament for the treatment of hypercholesterolemia in a subject in need thereof.